telmisartan has been researched along with MPTP Neurotoxicity Syndrome in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Garrido-Gil, P; Guerra, MJ; Joglar, B; Labandeira-Garcia, JL; Rodriguez-Perez, AI | 1 |
1 other study(ies) available for telmisartan and MPTP Neurotoxicity Syndrome
| Article | Year |
|---|---|
Involvement of PPAR-γ in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Benzimidazoles; Benzoates; Brain; Cell Death; Disease Models, Animal; Dopaminergic Neurons; Encephalitis; Gene Expression Regulation; Lectins; Leukocyte Common Antigens; Male; Mass Spectrometry; Mice; Mice, Inbred C57BL; Mice, Knockout; Microglia; MPTP Poisoning; PPAR gamma; Receptor, Angiotensin, Type 1; Telmisartan; Tyrosine 3-Monooxygenase | 2012 |